Dr Michel Ducreux talks to ecancer at ESMO 2012 in Vienna about emerging therapies for pancreatic cancer.

The prognosis for pancreatic cancer is often very poor with overall survival averaging 6 months with metastasis.

Dr Ducreux discuss on going trials that are testing the new compounds nab-paclitaxel and gemcitabine against the standard treatments. In addition the compund TH302, which fights against the cells even with hypoxia, was tested in comination with gemcitabine.

Filming supported by Amgen